1. Home
  2. AUGO vs ABVX Comparison

AUGO vs ABVX Comparison

Compare AUGO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AUGO

Aura Minerals Inc.

HOLD

Current Price

$60.30

Market Cap

6.0B

Sector

N/A

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$96.91

Market Cap

7.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUGO
ABVX
Founded
1946
2013
Country
United States
France
Employees
1462
69
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
7.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AUGO
ABVX
Price
$60.30
$96.91
Analyst Decision
Strong Buy
Buy
Analyst Count
3
13
Target Price
$67.60
$131.31
AVG Volume (30 Days)
700.8K
2.2M
Earning Date
05-06-2026
03-23-2026
Dividend Yield
1.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$91.05
$52.14
Revenue Next Year
$17.09
$4,132.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.55
$5.75
52 Week High
$110.32
$148.83

Technical Indicators

Market Signals
Indicator
AUGO
ABVX
Relative Strength Index (RSI) 38.62 41.67
Support Level $59.30 $87.60
Resistance Level $77.01 $131.50
Average True Range (ATR) 4.07 7.71
MACD -0.96 -1.68
Stochastic Oscillator 29.98 41.16

Price Performance

Historical Comparison
AUGO
ABVX

About AUGO Aura Minerals Inc.

Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments include: Minosa Mine, Apoena Mine, the Aranzazu Mine, Almas Mine, Borborema Mine and Serra Grande Mine. It derives maximum revenue from Aranzazu Mine. The company's growth projects include: Matupa in Brazil, and Era Dorada in Guatemala. whereas its exploration projects include: Carajas, in Brazil, and Tolda Fria in Colombia.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: